A study of the pharmacokinetic interaction between lamivudine and alpha interferon

European Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2000, Pages 289-292

  Johnson, M A ^b   Jenkins, J M ^a   Bye, C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Alpha interferon; Hepatitis B virus; Lamivudine

Indexed keywords

LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVERSE DRUG REACTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG COMBINATIONS; HALF-LIFE; HEPATITIS B; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; METABOLIC CLEARANCE RATE;

EID: 0033926128     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000148     Document Type: Article

References (13)

1. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998-99. Datapharm Publications Ltd, London, UK
2. Harker AJ, Evans GL, Hawley AE, Morris DM (1994) High-performance liquid Chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr Biomed Appl 657: 227-232
3. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA (1996) Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40: 1514-1519
4. Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, De Noord OE, Guentert TW (1989) Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 27: 795-802
5. Johnson MA, Moss J, Filip K, Horak J (1998a) The safety and pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 54: 363-366
6. Johnson MA, Yuen GJ, Daniel MJ, Plumb R, Moss J, De Broe M (1998b) Pharmacokinetics of lamivudine in patients with impaired renal function including those on haemodialysis. Br J Clin Pharmacol 46: 21-27
7. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes G (1999) The clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36: 41-66
8. Meredith CG, Christian CD, Johnson RF, Troxell R, Davis GL, Schenker S (1985) Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 37: 396-401
9. Mutimer D, Elias E, Johnson M, Barrett C, Grellier L (1998) Combination alpha interferon and lamivudine therapy for alpha-interferon resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 28: 923-929
10. Radwanski E, Perentesis G, Jacobs S, et al. (1987) Pharmacokinetics of interferon α-2b in volunteers. J Clin Pharmacol 27: 432-435
11. Wills RJ (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390-399
12. Wills RJ, Dennis S, Spiegel HE, et al. (1984) Inteferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 35: 722-727
13. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK (1995) Pharmacokinetics, absolute bioavailability and absorption characteristics of lamivudine. J Clin Pharmacol 35: 1174-1180